Lion City: Brewing outlet industry observation

The low listing threshold and the enthusiasm of the SGX are attractive

When it comes to Chinese pharmaceutical companies that used to be listed in Singapore, people will soon jump out of the name

The same path, from the listing in Singapore in 2007, to the delisting and then return to the Main Board of Hong Kong, Sihuan Bio only took 3 years

Whether it was three years or more, Chinese stocks in that period were snubbed in Singapore, and the price-earnings ratio was generally low

However, change is happening

The other side: the change of the SGX

In 2021, SGX introduced the Main Board Listing Rules for Special Purpose Acquisition Companies (SPAC), becoming the first financial centre

R&D customers noticed that Xiangfeng Investment has continued to deepen the medical and health field in China for many years, and invested in Microchip Bio, Hebo Pharmaceutical and Ruike Bio

In July, singapore exchanges and the New York Stock Exchange signed a memorandum of understanding outlining the terms of the agreement to collaborate

There is no doubt that SGX hopes that through this cooperation, more companies will be attracted to list in

Chinese companies that are "struggling" in the United States see new options

Currently, SGX has set up a main board and a Kelly board

The low listing threshold coupled with the enthusiasm of the SGX is likely to change the listing plans

Ambition: Backed by the entire ASEAN market

In fact, in addition to the capital market, singapore's market potential to link the whole of ASEAN has become increasingly attractive

The 2022 white paper released by the Singapore Economic Development Board, "Accelerating the Development of the ASEAN Market and Helping Chinese Biomedical Enterprises Expand the Global Market", mentions that in the past 20 years, with the steady recovery of the overall ASEAN economy, the middle class is rising

Source| the 2022 white paper "Accelerating the Development of the ASEAN Market and Helping Chinese Biomedical Enterprises Expand the Global Market"

Specific to Singapore, from the latest released GDP figures, Singapore achieved economic growth of 7.

Recently, the actions of WuXi AppTec and WuXi Biologics in Singapore have attracted attention
from the outside world.
In fact, there are currently more than 65 companies in Singapore for drug development
in the biopharmaceutical sector.
Among multinational pharmaceutical companies, Novartis, Roche, Pfizer and Bayer have set up R&D centers
in Singapore for the Asia-Pacific region.
In February this year, Kingsway Technology built a manufacturing base of more than 30,000 square feet in Singapore, with highly automated protein production and gene synthesis service equipment, and increased the scale of
the company's protein and gene synthesis automation platform.

In addition, after the new crown epidemic, Singapore has also become the new favorite
of many vaccine research and development companies.
In June this year, China Kexing opened a research facility and international business headquarters
in Singapore.
As a vaccine developer, BioNTech in Germany took the lead in Singapore's first Asia-Pacific regional headquarters in June last year and established an automated mRNA vaccine production plant
.
Sanofi will also build a vaccine production plant
in Singapore.

Linkages: Projects and investments in China

In fact, Singapore is also actively involved in the development of
China's biomedical industry.
Guangzhou, on the other hand, is undoubtedly the most preferred place
for the industrial connection between the two countries.

In the past few years, Singapore has developed rapidly in the field of cell therapy, with several CAR-T trials for leukemia and lymphoma indications conducted in singapore's large academic centres
.
Singapore Baekser Biotech cooperated with Science City (Guangzhou) Group to build a BIO-pharmaceutical production base and settled in Guangzhou Knowledge City
.
This is also the largest production base
of immune cell drugs in South China.
Another Singaporean company engaged in cell therapy development, Lai'en Biotech, signed an innovative drug research and development and production base project with Guangzhou Kai Development Zone this year, which will integrate TCR-T cell therapy research and development, production and clinical integration platform
.

In terms of investment, not long ago, the Singapore Government Investment Corporation participated in the B round of financing of China Blood Products Company Taibang Biotech, involving a total amount of US$300
million.

It should be said that today's Singapore is a re-departure
after the "Four Little Tigers" period.
From capital to industry, the dynamism and potential of emerging markets will have the potential to
change the direction of the biomedical industry.
The warm "southeast wind" may be able to blow away the chill of the "west wind"
.